ClinicalTrials.gg
CompletedNCT00312845Updated Jun 25, 2012Results posted

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

A Phase 3 interventional study of Bortezomib + Rituximab and Rituximab in Non-Hodgkin's Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 206 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-25.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
676
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies testing bortezomib in Lymphoma, Non-Hodgkin — none open to participants now, none under way, none of them phase 3. Bortezomib · Lymphoma, Non-Hodgkin.

Enrollment
Largest of 32
676 · median 33
Started
2006
with 7 others
Phase 3
Only one
of the 35
Registered
13th of 35
by date
Lead sponsor
2 of 35
Millennium Pharmaceuticals, Inc.

Among the 35 studies testing bortezomib in Lymphoma, Non-Hodgkin, this one has the largest enrollment of the 32 interventional ones that give a count, is one of 8 that started in 2006, is the only one in phase 3, and was the 13th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

None of the 35 studies testing bortezomib in Lymphoma, Non-Hodgkin is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies testing bortezomib in Lymphoma, Non-Hodgkin as a file.
02

Study summary

The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) who never received rituximab or who have previously responded to rituximab. This is an international study being conducted in the United States and in many countries around the world. A complete list of study locations is listed below.

03

Conditions studied

  • Non-Hodgkin's Lymphoma

Keywords

  • B-cell Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study:

  • Man or woman and age 18 years or older
  • Diagnosis of follicular B-NHL of the following subtypes (World Health Organization [WHO] classification 1997): follicular lymphoma (FL) (Grades 1 and 2).
  • Documented relapse or progression following prior antineoplastic treatment. New lesions or objective evidence of progression of existing lesions must document relapse or progression following the previous therapy.

If any prior regimen included rituximab, the subject must have responded (complete response [CR], unconfirmed complete response [CRu], partial response [PR]), and the time to progression (TTP) from the first dose of rituximab must have been 6 months or more.

  • At least 1 measurable tumor mass (greater than 1.5 cm in the longest dimension and greater than 1.0 cm in the short axis) that has not been previously irradiated, or has grown since previous irradiation
  • In the opinion of the investigator the decision to initiate treatment is justified to manage the subject's lymphoma
  • No active central nervous system lymphoma
  • [ECOG] status ≤ 2
  • Female subjects must be (for at least 6 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test at screening.
  • Subjects (or their legally acceptable representatives) must have signed an document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
  • In countries where health authorities have approved the pharmacogenomic testing, subjects or their legally acceptable representatives must have signed a separate informed consent that they agree to participate in the genetic part and protein testing part of the study; participation in the genetic and protein testing component is mandatory for pharmacogenomics testing, but optional for serum protein testing and future testing.

Exclusion criteria

Exclusion Criteria:

Potential subjects who meet any of the following criteria will be excluded from participating in the study:

  • Diagnosed or treated for a other than NHL within 1 year of randomization, or who were previously diagnosed with a malignancy other than NHL and have any radiographic or biochemical marker evidence of malignancy. Subjects with completely resected basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy are not excluded.
  • Clinical evidence of a transformation from indolent NHL to a more aggressive form of NHL.
  • History of disallowed therapies:

    • Prior treatment with VELCADE
    • Antineoplastic (including unconjugated therapeutic antibodies), experimental, or radiation therapy within 3 weeks before randomization
    • Nitrosoureas within 6 weeks before randomization
    • Radioimmunoconjugates or toxin immunoconjugates within 10 weeks before randomization
    • Stem cell transplant within 6 months before randomization
    • Major surgery within 2 weeks before randomization
  • Residual toxic effects of previous therapy or surgery of Grade 3 or worse
  • Peripheral neuropathy or neuropathic pain of Grade 2 or worse
  • Have received an experimental drug or used an experimental medical device within 21 days before the planned start of treatment.
  • History of allergic reaction attributable to compounds containing boron or mannitol
  • Known anaphylaxis or immunoglobulin E (IgE)-mediated to murine proteins or to any component of rituximab including polysorbate 80 and sodium citrate dihydrate
  • Concurrent treatment with another agent
  • Female subject who is pregnant or breast-feeding
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
676 participants (actual)

Study arms

  • Experimental
    Bortezomib + Rituximab

    Drug: Bortezomib + Rituximab

  • Active comparator
    Rituximab

    Drug: Rituximab

Interventions

  • DrugBortezomib + Rituximab

    Drug pages: Bortezomib · Rituximab

    VELCADE for Injection will be administered weekly on Days 1,8,15, and 22 of a 35-day cycle in combination with 4 doses of rituximab once a week on Days 1,8,15, and 22 of Cycle 1 and in combination with a single dose of rituximab on Day 1 of Cycles 2 to 5.

  • rituximab once a week on Days 1,8,15, and 22 of Cycle 1, and as a single dose on Day 1 of Cycles 2 to 5 (for a total of 8 doses).

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    Progression free survival is defined as time from randomization to progressive disease or death due to any cause, whichever occurs first.

    Time frame: Subjects are followed until progressive disease/death or the end of the study. The median follow up time is 33.9 months.

Secondary outcomes

  1. Overall Response Rate

    Overall response rate is defined as Complete Response (CR) + Complete Response Unconfirmed (CRu) + Partial Response (PR) using International Working Group Criteria (IWGC) and Independent Radiographic Review results and clinical results. The IWGC CR requires complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms, and normalization of lactic dehydrogenase and bone marrow involvement. CRu requires more than 75% reduction in sum of product of nodes (SPD). PR requires moer than 50% reduction in SPD.

    Time frame: Subjects are followed until progressive disease/death or the end of the study. The median follow up time is 33.9 months.

07

Results

Posted Jul 26, 2011

Participant flow

Participant flow — Overall Study
MilestoneBortezomib + RituximabRituximab
Started336340
Completed237245
Not completed9995
Withdrew: Adverse event195
Withdrew: Death22
Withdrew: Withdrawal by subject146
Withdrew: Disease progression5677
Withdrew: Lost to follow-up20
Withdrew: Other65

Outcome measures

PrimaryProgression Free Survival

Progression free survival is defined as time from randomization to progressive disease or death due to any cause, whichever occurs first.

Time frame:
Subjects are followed until progressive disease/death or the end of the study. The median follow up time is 33.9 months.
Reported as:
Median · days
Progression Free Survival
daysBortezomib + RituximabRituximab
Progression Free Survival389 (351 to 456)334 (278 to 365)
Statistical analysis
  • Bortezomib + Rituximab vs Rituximab · Log Rank · p = 0.039
SecondaryOverall Response Rate

Overall response rate is defined as Complete Response (CR) + Complete Response Unconfirmed (CRu) + Partial Response (PR) using International Working Group Criteria (IWGC) and Independent Radiographic Review results and clinical results. The IWGC CR requires complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms, and normalization of lactic dehydrogenase and bone marrow involvement. CRu requires more than 75% reduction in sum of product of nodes (SPD). PR requires moer than 50% reduction in SPD.

Time frame:
Subjects are followed until progressive disease/death or the end of the study. The median follow up time is 33.9 months.
Reported as:
Number · participants
Overall Response Rate
participantsBortezomib + RituximabRituximab
Overall Response Rate199160
Statistical analysis
  • Bortezomib + Rituximab vs Rituximab · Cochran-Mantel-Haenszel · p = <0.001

Adverse events

Collected over the end of study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bortezomib + Rituximab—59/334 (17.7%)288/334 (86.2%)
Rituximab—37/339 (10.9%)232/339 (68.4%)
Most frequent serious events
Showing 10 of 107
Most frequent serious events
EventBortezomib + RituximabRituximab
PneumoniaInfections and infestations7/3343/339
PyrexiaGeneral disorders6/3342/339
DiarrhoeaGastrointestinal disorders5/3342/339
Febrile neutropeniaBlood and lymphatic system disorders5/3343/339
Herpes zosterInfections and infestations4/3340/339
VomitingGastrointestinal disorders4/3341/339
HypersensitivityImmune system disorders4/3341/339
HypotensionVascular disorders4/3340/339
SepsisInfections and infestations3/3340/339
Abdominal painGastrointestinal disorders2/3342/339
Most frequent other events
Showing 10 of 19
Most frequent other events
EventBortezomib + RituximabRituximab
FatigueGeneral disorders75/33427/339
CoughRespiratory, thoracic and mediastinal disorders51/33431/339
Pain in extremityMusculoskeletal and connective tissue disorders46/33415/339
HeadacheNervous system disorders42/33424/339
ParaesthesiaNervous system disorders39/33410/339
Back painMusculoskeletal and connective tissue disorders37/33425/339
ThrombocytopeniaBlood and lymphatic system disorders32/33413/339
InsomniaPsychiatric disorders30/33418/339
ChillsGeneral disorders28/33417/339
PruritusSkin and subcutaneous tissue disorders25/33415/339

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Bortezomib + RituximabRituximabTotal
<=18 years000
Between 18 and 65 years243242485
>=65 years9398191
Age Continuous
Age Continuous(years)Bortezomib + RituximabRituximabTotal
Mean56.8 ± 11.1257.3 ± 1257 ± 11.56
Sex: Female, Male
Sex: Female, Male(Participants)Bortezomib + RituximabRituximabTotal
Female164203367
Male172137309
Region of Enrollment
Region of Enrollment(participants)Bortezomib + RituximabRituximabTotal
United States141630
Portugal111223
Slovakia7815
Greece112
Thailand213
Spain9514
Ukraine131124
Israel7714
Russian Federation5255107
Italy141529
India172441
France131023
Australia538
South Africa224
China464086
Korea, Republic of437
Finland123
United Kingdom91019
Hungary369
Czech Republic181735
Mexico9817
Canada91019
Argentina257
Brazil182139
Belgium181937
Poland242145
Romania628
Germany033
Sweden235
08

Study locations

206 sites
  • East Alabama Medical Center
    Opelika,, Alabama, United States
  • Central Hematology Oncology Medical Group, Inc
    Alhambra, California 91801, United States
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • Providence Saint Joseph Medical Center
    Burbank, California 91505, United States
  • St. Jude Heritage Medical Group
    Fullerton, California 92835, United States
  • Wilshire Oncology Medical Group, Inc.
    La Verne, California 91790, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • North Valley Hematology Oncology
    Mission Hills, California 91345, United States
  • University of California, Irvine Medical Center
    Orange, California 92868, United States
  • Ventura County Hematology-Oncology Specialists
    Oxnard, California 93030, United States
  • Cancer Care Associates Medical Group, Inc.
    Redondo Beach, California 90277, United States
  • Central Coast Medical Oncology Corporation
    Santa Maria, California 93454, United States
  • Norwalk Medical Group
    Norwalk, Connecticut, United States
  • Hematology Oncology PC
    Stamford, Connecticut, United States
  • Integrated Community Oncology Network
    Jacksonville, Florida, United States
  • Innovative Clinical Research of South Florida
    Miami, Florida, United States
  • Palm Beach Cancer Institute
    West Palm Beach, Florida, United States
  • Emory Univeersity ,Winship Cancer Institute
    Atlanta, Georgia, United States
  • Suburban Hematology-Oncology Associates
    Lawrenceville, Georgia 30045, United States
  • Northwest Georgia Oncology Centers, P.C.
    Marietta, Georgia 30060, United States
  • North Idaho Cancer Center
    Coeur D Alene, Idaho, United States
  • Investigative Clinical Research of Indiana
    Indianapolis, Indiana, United States
  • Siouxland Hematolgoy-Oncology Associates
    Sioux City, Iowa, United States
  • Kansas City Cancer Center, LLC
    Kansas City, Kansas 66210, United States
  • Louisville Oncology
    Louisville, Kentucky, United States
  • Hematology & Oncology Specialists
    Metairie, Louisiana, United States
  • Sinai Hospital
    Baltimore, Maryland, United States
  • Hattiesburg Clinic
    Hattesburg, Missouri, United States
  • Southeastern Medical Oncology Center
    Goldsboro, North Carolina 27530, United States
  • Oregon Health & Science University
    Portland, Oregon, United States
  • Lancaster Cancer Center, Ltd.
    Lancaster, Pennsylvania 17601, United States
  • The Western Pennsylvania Hospital
    Pittsburg, Pennsylvania, United States
  • South Carolina Oncology Associates, PA
    Columbia, South Carolina 29210, United States
  • South Carolina Oncology Associates
    Columbia, South Carolina, United States
  • Vanderbilt University
    Nashville, Tennessee 37232, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas, United States
  • Oncology Consultants
    Houston, Texas 777024, United States
  • South Texas Oncology and Hematology
    San Antonio, Texas, United States
  • Medical College of Wisconsin Milwaukee
    Milwaukee, Wisconsin, United States
  • Higa San Martin
    La Plata - Buenos Aires, Argentina
  • Hospital Professor Rodolfo Rossi
    La Plata - Buenos Aires, Argentina
  • Centro Oncologico Integracion Regional
    Mendoza, Argentina
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Peter MacCallum Cancer Institute
    East Melbourne, Victoria 3002, Australia
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Fremantle Hospital
    Fremantle, Western Australia 6160, Australia
  • ULB Erasme
    Anderlecht, 1070, Belgium
  • AZ Stuivenberg
    Antwerpen, 2060, Belgium
  • AZ Sint Jan
    Brugge, 8000, Belgium
  • Institute J. Bordet
    Bruxelles, 1000, Belgium
  • Clinique Notre Dame
    Charleroi, 6000, Belgium
  • UZ Antwerpen - Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • UZ Gent - Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • Virga Jesse Ziekenhuis, Dienst Hematologie
    Hasselt, 3500, Belgium
  • CHR La Citadelle
    Liege, 4000, Belgium
  • CHU Sart Tilman
    Liege, 4000, Belgium
  • Heilig Hart Roeselare
    Roeselare, 8800, Belgium
  • Servico de Oncologia do Hospital Sao Lucas da PUC do rio Grande do Sul
    Porto Alegre, Rio Grande do Sul 90610-00, Brazil
  • Instituto Nacional de Cancer
    Rio de Janeiro, 20231-050, Brazil
  • Hospital Brigadeiro
    Sao Paulo, 01404-901, Brazil
  • Faculdade de Medicina do ABC
    Sao Paulo, 09060-650, Brazil
  • Toronto Sunnybrook Regional Cancer Centre
    Toronto, Ontario, Canada
  • University Health Network - Princess Margaret Hospital
    Toronto, Ontario, Canada
  • Juravinski Cancer Centre
    Hamilton, Canada
  • West China Hospital of Sichuan
    Chengdu, Sichuan 610041, China
  • Cancer Hospital (Institute), CAMS&PUMC
    Beijing, 100021, China
  • Beijing Cancer Hospital
    Beijing, 100036, China
  • Peking University People's Hospital
    Beijing, 100044, China
  • Affiliated Hospital of the Academy of Military Medical Sciences
    Beijing, 100071, China
  • Cancer Center, Sun Yat-Sen University
    Guangzhou, 510060, China
  • Peking University Third Hospital
    Haidian District Beijing, 100083, China
  • RuiJin Hospital
    Shanghai, 200025, China
  • Cancer Hospital - FuDan University
    Shanghai, 200032, China
  • Bank of Cyprus Oncology Centre
    Nikosia, 2006, Cyprus
  • Fakultni nemocnice Brno
    Brno, 625 00, Czech Republic
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czech Republic
  • Fakultni nemocnice Olomouc
    Olomouc, 775 20, Czech Republic
  • Vseobecna Fakultni Nemocnice
    Praha, 2, Czech Republic
  • Paijat - Hameen Keskussairaala
    Lahti, 15850, Finland
  • Satakunnan Keskussairaala
    Pori, 28500, Finland
  • Institut Bergonie
    Bordeaux, 33076, France
  • Clinique Victor Hugo
    Le Mans, 72015, France
  • Hopital Claude Huriez
    Lille, 59037, France
  • Centre Léon Bérard
    Lyon, 69373, France
  • Hopital Hotel Dieu
    Nantes, 44098, France
  • Service des Maladies due sang - Hopital haut Leveque
    Pessac, 33604, France
  • Centre Hospitalier Lyon Sud
    Pierre Benite, 69495, France
  • Onkologische Schwerpunktpraxis
    Herrsching, 82211, Germany
  • Universitatsklinikum Munster - Klinik fur Innere Medizin
    Munster, Germany
  • Praxis für Hämetologie und Oncologie
    Würzburg, 97070, Germany
  • Laiko General Hospital of Athens - 1st Internist Clinic - Hematology Department
    Athens, 11527, Greece
  • University General Hospital Attikon - 2nd Department of Internal Medicine - Propedeutic & Research Institute
    Athens, 12462, Greece
  • University Hospital of Patras - Department of Internal Medicine - Hematology Division
    Rio Patras, 26500, Greece
  • Debreceni Egyetem, Orvos- es Egeszsegtudomanyl Centrum, iii. Belgyogyaszati Klinika
    Debrecen, H-4004, Hungary
  • Petz Aladar County Hospital
    Gyor, 9024, Hungary
  • SZEgedi Tudomanyegyetem, II Belgyaszati Klinika
    Szeged, H-6720, Hungary

Showing the first 100 of 206 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Zinzani PL, Khuageva NK, Wang H, Garicochea B, Walewski J, Van Hoof A, Soubeyran P, Caballero D, Buckstein R, Esseltine DL, Theocharous P, Enny C, Zhu E, Elsayed YA, Coiffier B. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naive or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. J Hematol Oncol. 2012 Oct 22;5:67. doi: 10.1186/1756-8722-5-67. PubMed 23088650 ↗
  • Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011 Aug;12(8):773-84. doi: 10.1016/S1470-2045(11)70150-4. Epub 2011 Jul 1. PubMed 21724462 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Jun 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2006
First posted
Apr 11, 2006
Start
Mar 2006
Primary completionActual
Jun 2010
CompletionActual
Jul 2010
Results first posted
Jul 26, 2011
Last update
Jun 25, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00312845
Responsible party
Sponsor
First posted
Apr 11, 2006
Start date
Mar 2006
Primary completion
Jun 2010
Completion
Jul 2010
Results posted
Jul 26, 2011
Last update
Jun 25, 2012

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bortezomib · Rituximab

Start the discussion